DIVIGEL 0.1% (Estradiol)
DIVIGEL 0.1% (Estradiol)
DIVIGEL 0.1% (Estradiol)
  • Load image into Gallery viewer, DIVIGEL 0.1% (Estradiol)
  • Load image into Gallery viewer, DIVIGEL 0.1% (Estradiol)
  • Load image into Gallery viewer, DIVIGEL 0.1% (Estradiol)

DIVIGEL 0.1% (Estradiol)

Vendor
SEARCHLIGHT PHARMA
Regular price
$59.99 USD
Sale price
$59.99 USD
Regular price
Sold out
Unit price
per 

Shipped from Canada.

prescription

What is this medication?

Estradiol, Divigel
Female Reproductive Hormone; Estrogen

Estrogen replacement therapy in estrogen deficiency states.

“ALERT: US Boxed Warning

Endometrial cancer:
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Use adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal genital bleeding.

Cardiovascular disease:
Do not use estrogen-alone therapy for the prevention of cardiovascular disease. The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) (0.625 mg) alone, relative to placebo.

Do not use estrogen plus progestin therapy for the prevention of cardiovascular disease. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism, stroke, and myocardial infarction in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) (2.5 mg), relative to placebo.

Breast cancer:
The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.

Dementia:
Do not use estrogen-alone therapy for the prevention of dementia. The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women ≥65 years of age during 5.2 years of treatment with daily CE (0.625 mg) alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.

Do not use estrogen plus progestin therapy for the prevention of dementia. The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women ≥65 years of age during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.

Risk vs benefits:
Only daily oral CEs (0.625 mg) and daily oral CE (0.625 mg) and MPA (2.5 mg) were studied in the estrogen-alone and estrogen plus progestin substudies of the WHI, respectively. Therefore, the relevance of the WHI findings regarding the adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen alone products is not known. Likewise, the relevance of the WHI findings regarding the adverse cardiovascular events, dementia, and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestin products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of the risks for other products. Discuss with your patient the benefits and risks of estrogen-alone or estrogen plus progestin therapy, taking into account her individual risk profile. Prescribe estrogens with or without progestins at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.”

How does this medication work? 

Estradiol acts like natural estradiol to support development and function of the female reproductive system, secondary sex characteristics and urogenital structures.  Estradiol inhibits the pituitary release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) thereby inhibiting ovulation.

How should I take this medication?

Vasomotor Symptoms (Moderate to Severe) Associated with Menopause
Apply the contents of one packet daily and adjust dose as needed to the recommended maximal daily dose.

*When treating symptoms of menopause, evaluate hormone therapy routinely for appropriate dose, duration, and route of administration for each individual patient based on treatment goals, risk factors, and overall health. 

Apply the entire contents of the Divigel packet to the right or left upper thigh each day (rotate sites).  Do not apply the gel to your face, breasts, vagina, or irritated/broken skin.  Allow the gel to dry before dressing.

What should I watch for while using this medication?

Do not use in women with an increased risk of invasive breast cancer

Do not use in women to prevent or treat dementia

Do not use unopposed estrogen in women with a uterus

Do not use in women with endometriosis

Use with caution in women with pre-existing hypertriglyceridemia

Use with caution in women with ovarian cancer

Use with caution in women with retinal vascular thrombosis

Use with caution in asthma, carbohydrate intolerance, cardiovascular disease, fluid retention, hepatic dysfunction, hypoparathyroidism, migraines, porphyria, and system lupus erythematosus

What if I miss a dose?

If you miss a dose of medication, try to take it as soon as possible. However, if it is almost time for your next dose, take only that scheduled dose. Do not take double or extra doses.

How should I store this medication?

Keep out of the reach of children at all times. Store at room temperature, 59 to 86° F (15 to 30° C). Protect from light. Keep the container tightly closed. Properly dispose of any unused medication after the expiration date.

What are the possible side effects of using this medication?

The frequency of side effects is not well defined and some of the adverse reactions are dependent on the dosage form and combination therapy used:

>10%

Cardiovascular: Edema (10% to 13%)

Central Nervous System: Headache (9% to 50%), pain (6% to 13%), depression (1% to 11%), anxiety (4% to 10%)

Dermatologic: Skin rash (7% to 10%)

Endocrine and Metabolic: Weight gain (4% to 10%)

Gastrointestinal: Abdominal pain (6% to 16%)

Genitourinary: Mastalgia (5% to 35%), vaginal hemorrhage (33%), breast tenderness (3% to 17%), endometrium disease (15%), breakthrough bleeding (6% to 11%), abnormal bleeding (4% to 10%)

Infection: Infection (3% to 12%), fungal infection (3% to 10%)

Neuromuscular and Skeletal: Arthralgia (4% to 12%), back pain (3% to 11%)

Respiratory: Nasopharyngitis (4% to 20%), upper respiratory tract infection (6% to 17%), flu-like symptoms (8% to 13%), sinusitis (4% to 13%), sinus headache (9% to 11%)